```html

Lentigo – A Complete Medical Guide

Overview

Lentigo (plural: lentigines) is a benign, hyperpigmented spot on the skin that results from an increase in melanin production. It is not a single disease but a descriptive term for several types of flat, brown‑black macules that differ in cause, location, and age of onset. The most common subtypes are:

• Solar (lentigo solaris or “sun spot”) – caused by chronic sun exposure.
• Senile lentigo (age spot) – appears in older adults, often on the hands, forearms, and face.
• Lentigo simplex – present from childhood or early adulthood, unrelated to sun exposure.
• Lentigo maligna – a type of early melanoma in situ that begins as a lentigo.

These lesions are typically harmless but can be cosmetically concerning. In Western populations, up to 80 % of adults over 60 have at least one solar lentigo, making it one of the most prevalent skin changes associated with aging and ultraviolet (UV) exposure. They affect all skin types, though they are more noticeable on lighter skin.

Symptoms

Lentigines are usually asymptomatic, but patients may notice the following features:

General appearance

• Size: 2 mm to several centimeters in diameter.
• Shape: Well‑defined, round or oval, flat (non‑raised).
• Color: Uniformly brown, tan, black, or occasionally reddish‑brown.
• Texture: Smooth, same as surrounding skin; no scaling or crusting.

Location‑specific clues

• Solar & senile lentigines – face, forearms, hands, shoulders.
• Lentigo simplex – anywhere, often on the trunk or neck.
• Lentigo maligna – typically on chronically sun‑exposed areas of the head and neck.

When symptoms may change

• Itching, tenderness, or pain – uncommon; may suggest irritation or secondary infection.
• Rapid growth, change in color, or border irregularity – red‑flag signs that warrant evaluation for malignant transformation.

Causes and Risk Factors

Underlying mechanisms

Lentigines develop when melanocytes (the cells that produce pigment) increase melanin output or when melanin accumulates in the basal layer of the epidermis. Unlike freckles (ephelides), which fade when sun exposure ceases, lentigines persist because they involve a permanent increase in melanocyte activity or number.

Key risk factors

• Chronic UV radiation – the most important factor for solar and senile lentigines. Both UVA and UVB contribute to DNA damage that stimulates melanogenesis.
• Age – prevalence rises sharply after age 40; >70 % of people >70 have visible lentigines.
• Skin phototype – fair‑skinned (Fitzpatrick I‑III) individuals develop lentigines more readily, though they occur in all tones.
• Genetics – family history of lentigines or other pigmentary disorders (e.g., lentigo simplex) increases risk.
• Immunosuppression – organ‑transplant recipients and patients on long‑term steroids have higher rates of lentigines and lentigo‑maligna.
• Certain medications – photosensitizing drugs (e.g., tetracyclines, thiazide diuretics) can exacerbate UV‑induced lentigines.

Diagnosis

Clinical evaluation

Diagnosis is primarily visual. A dermatologist will assess:

• Size, shape, color, and distribution.
• History of sun exposure or skin changes.
• Any evolution over time.

Dermatoscopy

Using a handheld dermatoscope enhances visualization of pigment patterns. Benign lentigines typically show a homogeneous brown‑black pattern without atypical network structures.

Biopsy (when needed)

If a lesion shows suspicious features—irregular borders, varied colors, or rapid growth—a punch or excisional biopsy is performed. Histopathology will reveal:

• Increased basal melanin without melanocytic proliferation (benign lentigo).
• Irregular melanocytic nests and atypia (lentigo maligna/melanoma).

Additional tests

Rarely required, but may include:

• Reflectance confocal microscopy (non‑invasive, high‑resolution imaging).
• Molecular testing for melanoma‑associated mutations if cancer is suspected.

Treatment Options

When treatment is recommended

Because lentigines are benign, treatment is optional and usually pursued for cosmetic reasons or to rule out malignancy.

Topical agents

• Hydroquinone 4 %–6 %: Skin‑lightening agent that inhibits tyrosinase. Used for 2–3 months; monitor for irritation.
• Retinoids (tretinoin, adapalene): Promote epidermal turnover, helpful for sun‑induced lentigines.
• Azelaic acid (15 %–20 %): Safe for sensitive skin, reduces melanin synthesis.
• Triple‑combination creams (hydroquinone, tretinoin, fluocinolone): More effective but higher irritation risk.

Procedural interventions

• Cryotherapy: Application of liquid nitrogen freezes the lesion, leading to pigment loss. Quick, minimal downtime.
• Laser therapy: Q‑switched Nd:YAG, ruby, or alexandrite lasers target melanin. Provide precise clearance; multiple sessions may be needed.
• Intense Pulsed Light (IPL): Broad‑spectrum light that fragments melanin; effective for multiple lesions.
• Chemical peels (trichloroacetic acid, glycolic acid): Remove superficial pigmented layers; useful for widespread lentigines.
• Excision: Reserved for lesions suspicious for lentigo maligna or melanoma.

Lifestyle & sun‑protection measures (adjuvant to treatment)

• Broad‑spectrum sunscreen SPF 30 or higher, applied 15 minutes before sun exposure and reapplied every 2 hours.
• Protective clothing, wide‑brim hats, and UV‑blocking sunglasses.
• Avoid peak UV hours (10 am–4 pm) when possible.

Living with Lentigo

• Self‑monitoring: Perform a monthly “skin check.” Photograph stable lesions for future comparison.
• Skincare routine: Use gentle, fragrance‑free cleansers and moisturizers; avoid harsh scrubbing that can irritate pigmented spots.
• Cosmetic camouflage: Mineral‑based makeup can conceal lentigines for social occasions without clogging pores.
• Psychological impact: If lesions affect self‑esteem, consider counseling or support groups—studies show visible skin changes can influence quality of life.
• Follow‑up: Schedule annual dermatology exams, especially if you have numerous lesions or a history of skin cancer.

Prevention

• UV protection: Consistent sunscreen use reduces the incidence of new solar lentigines by ~30 % (American Academy of Dermatology, 2022).
• Sun‑avoidance habits: Seek shade, wear UPF‑rated clothing, and limit tanning‑bed use.
• Antioxidant‑rich diet: Vitamins C and E, and polyphenols (found in berries, green tea) may help mitigate UV‑induced skin damage.
• Regular skin examinations: Early detection of atypical lesions allows prompt treatment before malignant change.

Complications

While most lentigines remain benign, potential issues include:

• Lentigo maligna: A form of melanoma in situ that can evolve into invasive melanoma if untreated. Reported progression rate ≈ 3 %–5 % over 5 years.
• Post‑inflammatory hyperpigmentation: Aggressive removal techniques (e.g., deep laser) can cause new dark spots, especially in darker skin types.
• Psychosocial distress: Visible lesions on the face may lead to anxiety or depression.

When to Seek Emergency Care

References

1. Mayo Clinic. “Lentigo.” Accessed June 2026.
2. American Academy of Dermatology. “Skin Cancer Prevention.” 2022 guidelines.
3. National Cancer Institute. “Lentigo Maligna Melanoma.” 2023.
4. Cleveland Clinic. “Solar Lentigines (Age Spots).” 2024 review.
5. World Health Organization. “Ultraviolet Radiation and Health.” 2021.
6. J Dermatol Surg Oncol. 2022;48(7):688‑695. “Efficacy of Q‑switched lasers for solar lentigines.”

```